Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole
Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole
复制标题
DOI：
10.1007/s00296-006-0212-6
复制
发表时间：
2006-11-01
影响因子：
4
通讯作者：
Darlington, L. Gail
中科院分区：
文献类型：
--
作者：
Forrest, Caroline M.;Stoy, Nicholas;Darlington, L. Gail
腺苷可以抑制活化的单核细胞和巨噬细胞释放肿瘤坏死因子-α（TNF-α），并可能有助于甲氨蝶呤和柳氮磺胺吡啶的抗炎活性。双嘧达莫抑制细胞摄取和腺苷代谢，因此，我们研究了双嘧达莫在类风湿性关节炎患者中的作用，试图减轻他们的症状。40例年龄在18-75岁的患者随机接受双嘧达莫400 mg/天或安慰剂治疗。在基线时和6个月内每月一次采集血样。嘌呤用HPLC法测定，细胞因子用ELISA法测定。治疗3个月后，新蝶呤水平和改良的健康评估问卷评分显着降低，但这些都没有保持。双嘧达莫对疾病的严重程度或嘌呤代谢产物、白细胞介素-1 β（IL-1 β）、IL-6、TNF-α、脂质过氧化产物、红细胞沉降率或C反应蛋白的水平没有影响。总之，类风湿性关节炎患者在用潘生丁治疗6个月后没有表现出临床改善。
Adenosine can suppress the release of tumour necrosis factor-alpha (TNF-alpha) from activated monocytes and macrophages, and may contribute to the anti-inflammatory activities of methotrexate and sulphasalazine. Dipyridamole inhibits the cellular uptake and metabolism of adenosine and we have, therefore, examined the effects of dipyridamole in patients with rheumatoid arthritis in an attempt to alleviate their symptoms. Forty patients aged 18-75 years were randomised to receive dipyridamole 400 mg/day or placebo. Blood samples were taken at baseline and at monthly intervals for 6 months. Purines were determined by HPLC and cytokines by ELISA. After 3 months of treatment there were significant reductions in neopterin levels and in the modified Health Assessment Questionnaire score, but these were not maintained. Dipyridamole had no effect on disease severity or the levels of purine metabolites, interleukin-1 beta (IL-1 beta), IL-6, TNF-alpha, lipid peroxidation products, erythrocyte sedimentation rate or C-reactive protein. In conclusion, rheumatoid arthritis patients showed no clinical improvement following treatment with dipyridamole for 6 months.